Press Releases

InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones

Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial of First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation San Francisco, CA – November 8, 2018 – InCarda Therapeutics, Inc....

InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation (PAF)

Flecainide administered via oral inhalation is well tolerated and elicits ECG changes suggestive of rapid drug delivery to heart Brisbane, California, June 7, 2017 – InCarda Therapeutics, Inc. (InCarda), a privately held biopharmaceutical company developing therapies for acute cardiovascular conditions via the inhalation route, today...

InCarda Therapeutics Elects Dr. Norbert Bischofberger to Board of Directors

San Francisco, California, June 7, 2016 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced the election of Norbert Bischofberger, Ph.D., to the company’s board of directors. Dr. Bischofberger has...

InCarda Therapeutics Establishes Subsidiary Business in Australia

San Francisco, California, December 1, 2015 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development and commercialization of therapies for cardiovascular conditions via the inhalation route, today announced that it has established a subsidiary business in Australia. InCarda is planning to...

InCarda Therapeutics Issued Broad Patents in U.S., Australia and Canada

Palo Alto, California, October 6, 2015 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, today announced the issuance of patents in the United States, Australia and Canada, which...

InCarda Therapeutics Completes Over $5 Million Private Financing

San Francisco, California, April 28, 2015 – InCarda Therapeutics, Inc. (InCarda), a privately-­‐held biotechnology company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, today announced the completion of a Series A financing. In this financing, InCarda raised...